Junshi Biologics' JS110 (XPO1 inhibitor) clinical trial application was approved by the US FDA

Shanghai, August 25, 2022 /PRNewswire/ -- On August 25, 2022, Beijing time, Junshi Biologics announced that the clinical trial application of the XPO1 inhibitor WJ01024 tablets (project code: JS110) jointly developed by the company and Micro Bio has been approved by
the US Food and Drug Administration (FDA).

XPO1 is the primary protein that mediates nuclear output and plays a vital role
in maintaining cellular homeostasis.

JS110 is a small molecule inhibitor of the nucleo-exporting protein XPO1 that is clinically intended for the treatment of patients with
advanced tumors.

In April 2021, the clinical trial application for JS110 was approved by
the State Drug Administration (NMPA).

Concentrate:

1.

2.

References:

1.

About Junshi Biology

Founded in December 2012, Junshi Biologics is an innovation-driven biopharmaceutical company
dedicated to the discovery, development and commercialization of innovative therapies.

With the core platform technology of protein engineering, Junshi Bio is at the forefront of international macromolecular drug research and development, and has obtained the first domestic anti-PD-1 monoclonal antibody NMPA listing approval, domestic anti-PCSK9 monoclonal antibody NMPA clinical application approval, the world's first therapeutic tumor anti-BTLA blocking antibody in China NMPA and the US FDA clinical application approval, and is currently carrying out a number of Phase I/II clinical trials
in China and the United States.

Since the beginning of the outbreak of the epidemic in 2020, Junshi Bio has responded quickly, joined hands with domestic and foreign scientific research institutions and enterprises to fight the epidemic, used technology accumulation to quickly develop a number of innovative drugs for the treatment of COVID-19, and actively assumed the social responsibility
of Chinese pharmaceutical enterprises 。 These include: Etersvimab (JS016), the first domestic antibody to enter the clinical stage and participate in the global anti-epidemic anti-COVID-19 neutralization antibody, was granted emergency use authorization in more than 15 countries and regions in 2021, and the new oral nucleoside anti-new coronavirus drug VV116 (JT001) has entered the international multi-center phase III registered clinical research stage, as well as other types of drugs, continuing to contribute to the global fight against the epidemic
.

At present, Junshi Bio has more than 3,100 employees around the world, distributed in San Francisco and Maryland, Shanghai, Suzhou, Beijing, Guangzhou and so on
.

Official WeChat: Junshi Bio

Source: Junshi Bio